CN
Search Within
Y0000458
应用筛选条件
关键词:'Y0000458'
显示 1-30 共 46 条结果 关于 "Y0000458" 范围 论文
Qian Xiang et al.
Pharmacology, 89(1-2), 105-110 (2012-03-09)
The aim of this study was to evaluate the pharmacogenetic variability in the disposition of repaglinide in healthy Chinese subjects. A single dose of 2 mg repaglinide was orally administered to 24 healthy Chinese subjects. The serum concentrations of repaglinide
Jie Zhu et al.
Pakistan journal of pharmaceutical sciences, 26(3), 577-584 (2013-04-30)
The effect of pitavastatin and SLCO1B1 genetic background on the pharmacokinetic and pharmacodynamic properties of repaglinide was investigated. In this randomized, placebo-controlled, crossover study, twelve healthy Chinese males were administered with pitavastatin 4 mg/d or the placebo for 5 d
M K Rawat et al.
Current drug delivery, 7(1), 44-50 (2010-01-05)
Repaglinide solid lipid nanoparticles (RG-SLN) were fabricated using stearic acid as lipid. Pluronic F68 (PLF68) and soya lecithin were used as a stabilizer. SLNs were prepared by modified solvent injection and ultrasonication methods. SLNs prepared with modified solvent injection method
Toshiyuki Kudo et al.
Drug metabolism and disposition: the biological fate of chemicals, 41(2), 362-371 (2012-11-10)
The plasma concentration of repaglinide is reported to increase greatly when given after repeated oral administration of itraconazole and gemfibrozil. The present study analyzed this interaction based on a physiologically based pharmacokinetic (PBPK) model incorporating inhibition of the hepatic uptake
Carolina Säll et al.
Drug metabolism and disposition: the biological fate of chemicals, 40(7), 1279-1289 (2012-03-28)
Repaglinide is presently recommended by the U.S. Food and Drug Administration as a clinical CYP2C8 probe, yet current in vitro and clinical data are inconsistent concerning the role of this enzyme in repaglinide elimination. The aim of the current study
Drug and therapeutics bulletin, 41(7), 52-54 (2003-07-26)
[symbol: see text] Nateglinide (Starlix-Novartis) and [symbol: see text] repaglinide (NovoNorm-Novo Nordisk) are two of a new class of orally active antidiabetic drugs, the meglitinides. They have a rapid-onset and short-lasting stimulating effect on insulin secretion. Both are licensed for
Christina Jarnert et al.
Diabetes & vascular disease research, 9(4), 287-295 (2012-03-02)
Microcirculatory and endothelial dysfunction are signs of cardiovascular engagement in patients with type 2 diabetes. This study tested whether glucose normalisation may reverse this. Thirty-nine T2DM patients (age 61±7 years, 58% females) with signs of mild diastolic dysfunction were randomised
Deaths in trials should always be reported.
Jeppe Schroll
BMJ (Clinical research ed.), 347, f4219-f4219 (2013-07-06)
Combination therapy in type 2 diabetes: the role of repaglinide.
R Moses
The Journal of the Association of Physicians of India, 49 Spec No, 62-68 (2001-03-10)
Vibeke Hatorp
Clinical pharmacokinetics, 41(7), 471-483 (2002-06-27)
Repaglinide is a novel, fast-acting prandial oral hypoglycaemic agent developed for the treatment of patients with type 2 diabetes whose disease cannot be controlled by diet and exercise alone. Although repaglinide binds to the sulphonylurea binding sites on pancreatic beta-cells
Rania N El-Shaheny
Journal of fluorescence, 22(6), 1587-1594 (2012-07-04)
A simple and highly sensitive spectrofluorimetric method was developed and validated for determination of the antidiabetic agent repaglinide (RG) in tablets. The proposed method is based on measurement of the native fluorescence of RG in 0.1 M H(2)SO(4)/methanol medium at
D R Owens et al.
Diabetes, nutrition & metabolism, 15(6 Suppl), 19-27 (2003-04-19)
The major contributory factor to increasing hyperglycaemia in established Type 2 diabetes mellitus (T2DM) appears to be the progressive delay and attenuation of the prandial insulin response. An important consequence of this derangement is that hepatic glucose production is no
Feng Jiang et al.
Biomedical and environmental sciences : BES, 25(1), 23-29 (2012-03-20)
To investigate a potential relationship between Solute carrier family 30 (zinc transporter) member 8 (SLC30A8) rs13266634 variant and efficacy of rosiglitazone or repaglinide in treating newly diagnosed Chinese type 2 diabetes patients. A total of 209 diabetic patients without any
P Raskin
Diabetes, obesity & metabolism, 10(12), 1167-1177 (2008-05-23)
Type 2 diabetes is characterized by decreases in insulin secretion and insulin sensitivity. Several classes of oral antidiabetic medications are currently approved for the treatment of type 2 diabetes. A stepwise treatment approach from monotherapy to combination therapy is traditionally
Current understanding regarding the role of repaglinide in post-prandial hyperglycemia.
P S Menon
The Journal of the Association of Physicians of India, 49 Spec No, 50-53 (2001-03-10)
Severe hypoglycaemia from repaglinide-brotizolam drug interaction: a case report and literature review.
M Khamaisi
Diabetic medicine : a journal of the British Diabetic Association, 29(9), 1214-1215 (2012-03-15)
Carlos del Pozo-Fernández et al.
Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 32(3), 367-373 (2012-05-18)
In this paper we analyse the discrepancies that exist in the widespread prescription of metformin in patients with type 2 diabetes and the lack of guidelines concerning its prescription in the different stages of renal failure. This cross-sectional study includes
R Moses
Expert opinion on pharmacotherapy, 1(7), 1455-1467 (2001-03-16)
Repaglinide is a novel insulin secretagogue that was developed as a prandial glucose regulator for the treatment of people with Type 2 diabetes mellitus. It is used flexibly, taken prior to meals, in order to limit subsequent postprandial blood glucose
Laxmikant Ramvallabh Zawar et al.
Chemical & pharmaceutical bulletin, 60(4), 482-487 (2012-04-03)
The influence of microwave technology on the in vitro dissolution rate and in vivo antihyperglycemic activity of a poorly water soluble drug, repaglinide (RG) was studied. Solid dispersions were prepared by conventional fusion method and microwave method using poloxamer 188.
Anna Gumieniczek et al.
Experimental diabetes research, 2012, 653678-653678 (2012-04-05)
The present study was undertaken to determine oxidative/nitrosative stress in aqueous humor of alloxan-induced hyperglycemic rabbits and to investigate the effects of two oral antidiabetic drugs, pioglitazone from peroxisome proliferator-activated receptor gamma (PPARγ) agonists and repaglinide from nonsulfonylurea K(ATP) channel
Odd Erik Johansen et al.
American journal of cardiovascular drugs : drugs, devices, and other interventions, 7(5), 319-335 (2007-10-24)
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia due to a combination of insulin resistance and impaired insulin secretion. The hyperglycemia is associated with an increased risk for micro- and macrovascular complications, and lowering fasting and postprandial hyperglycemia may
The role of prandial glucose regulation with repaglinide in addressing the problem of hypoglycemia in the treatment of type 2 diabetes.
D Owens
The Journal of the Association of Physicians of India, 49 Spec No, 54-61 (2001-03-10)
Cen Li et al.
Journal of chromatographic science, 50(8), 739-743 (2012-05-24)
This study used the general applicability of 2,6-didi-o-methyl-β-cyclodextrin (DM-β-CD) as the chiral selector in capillary electrophoresis for fast and efficient chiral separation of repaglinide enantiomers. A systematic study of the parameters affecting separation was performed with UV detection at 243
G E Rutten
Nederlands tijdschrift voor geneeskunde, 145(32), 1547-1550 (2001-08-30)
In about 25% of type 2 diabetes patients, good diabetes control is not attainable with oral blood-glucose lowering drugs. Furthermore, in many people with diabetes the disease deteriorates, despite the use of blood-glucose lowering medication, due to the decline of
Boggarapu Prakash Rao et al.
Pakistan journal of pharmaceutical sciences, 26(4), 707-713 (2013-07-03)
The full factorial design was employed to evaluate contribution of drug: polymer and Eudragit RS 100: Eudragit RL 100 on entrapment efficiency, time for maximum drug release, percentage of drug release. Floating microparticles were prepared using spray drying technique. Microparticles
Greg L Plosker et al.
PharmacoEconomics, 22(6), 389-411 (2004-04-22)
Repaglinide (Prandin), NovoNorm, GlucoNorm, an oral insulin secretagogue, was the first meglitinide analogue to become available for use in patients with type 2 diabetes mellitus. The drug lowers postprandial glucose excursions by targeting early-phase insulin release, an effect thought to
[Repaglinide (NN-623)].
Masafumi Matsuda et al.
Nihon rinsho. Japanese journal of clinical medicine, 60 Suppl 9, 555-558 (2002-10-22)
Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia.
V Ambavane et al.
Journal of postgraduate medicine, 48(3), 246-248 (2002-11-15)
R Moses
Diabetes, nutrition & metabolism, 15(6 Suppl), 33-38 (2003-04-19)
Type 2 diabetes mellitus (T2DM) is a progressive disorder requiring increasingly aggressive treatment to achieve and maintain target blood glucose concentrations in the presence of deteriorating insulin secretion and increasing insulin resistance. Diet and lifestyle modification are often sufficient initially;
Manthena V S Varma et al.
Pharmaceutical research, 30(4), 1188-1199 (2013-01-12)
Quantitative prediction of complex drug-drug interactions (DDIs) is challenging. Repaglinide is mainly metabolized by cytochrome-P-450 (CYP)2C8 and CYP3A4, and is also a substrate of organic anion transporting polypeptide (OATP)1B1. The purpose is to develop a physiologically based pharmacokinetic (PBPK) model
1/2